Localized muscle spasm as a manifestation of pembrolizumab-induced infusion reaction.
J Oncol Pharm Pract
; 27(5): 1270-1274, 2021 Jul.
Article
em En
| MEDLINE
| ID: mdl-33148131
ABSTRACT
INTRODUCTION:
As immune checkpoint inhibitors increasingly gain oncological utility, the incidence of unique adverse events may rise as well. The description and management of localized, recurrent muscle spasms secondary to pembrolizumab infusions has not previously been reported. CASE REPORT A 64-year-old male receiving pembrolizumab infusions experienced acute-onset, isolated spasms and pain occurring in cycles 2 through 5.Management andoutcome:
Pretreatment with intravenous lorazepam, diphenhydramine, famotidine, ondansetron, and fluids have led to spasm-free pembrolizumab infusions.DISCUSSION:
The purpose of this report is to provide the first known incidence and successful corrective measures taken for localized muscle spasms secondary to pembrolizumab infusion.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Espasmo
/
Anticorpos Monoclonais Humanizados
/
Inibidores de Checkpoint Imunológico
Limite:
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article